MAHA MEDICAL (MahaRX) Please wait...
MAHA MEDICAL (MahaRX) Please wait...
.
To establish ourselves as a trusted and reliable supplier of biotechnology, stem cell, and gene therapy products in Iran. To expand our product portfolio by partnering with leading global manufacturers. To provide exceptional customer service by delivering products on time and providing timely and accurate technical support.
Quality: We are committed to providing the highest quality products and services to our customers. Integrity: We operate with honesty, transparency, and ethical standards in all our dealings. Innovation: We strive to continuously innovate and improve our products and services to better serve our customers. Teamwork …
At Maha Medical, our mission is to become a leading player in the biotechnology, stem cell, and gene therapy markets in Iran. We aim to achieve this by providing our customers with the highest quality products and services, as well as leveraging the expertise and experience of our parent company, Nooraseman Holding.
Our vision is to become the leading provider of biotechnology, stem cell, and gene therapy products and services in Iran, known for our commitment to quality, integrity, and innovation. We aim to create a better future for our customers by delivering breakthrough solutions that improve human health and well-being.
FDA Approves first cellular therapy to treat patients with type 1 Diabets: The FDA has approved Lantidra, developed by CellTrans Inc., for the treatment of type 1 diabetes. Five participants in the clinical trial did not achieve any days of insulin independence. Adverse reactions varied among participants, with common ones including nausea, fatigue, anemia, diarrhea, and abdominal pain. Most participants experienced serious adverse reactions related to the infusion procedure and the use of immunosuppressive medications. Some serious reactions necessitated discontinuation of immunosuppressive drugs, resulting in the loss of islet cell function and insulin independence. Patient-directed labeling for Lantidra will provide information on its benefits and risks to patients with type 1 diabetes
The FDA has required Sarepta Therapeutics, Inc. to conduct a clinical study to confirm the clinical benefit of their drug Elevidys for patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene. The study, which is ongoing and fully enrolled, aims to evaluate the improvement in physical function and mobility in ambulatory DMD patients. The FDA will review the trial data promptly to determine if any further action, such as revising the drug’s indication or withdrawing it, is necessary. Elevidys received accelerated approval from the FDA
The drug was tested in a clinical study involving subjects aged 1 to 44 years, with the mean age being 17 years. The efficacy of Vyjuvek was demonstrated by improved wound healing, with 65% of treated wounds achieving complete closure compared to only 26% in the placebo group at 24 weeks. Two young patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB) also received Vyjuvek without any new safety concerns. Common adverse reactions associated with Vyjuvek include itching, chills, redness, rash, cough, and runny nose. Precautions during treatment include avoiding direct contact with treated wounds, washing hands and wearing protective gloves when changing dressings, and disinfecting and properly disposing of used dressings. Vyjuvek has received Orphan Drug, Fast Track, Regenerative Medicine Advanced Therapy
Stem cells are undifferentiated cells that have the extraordinary ability to develop into various specialized cell types in the body. They can be classified into different types, such as embryonic stem cells, adult stem cells, and induced pluripotent stem cells (iPSCs). Stem cell therapy involves the use of these cells to repair, replace, or regenerate damaged or diseased tissues. The applications of stem cell therapy are vast, ranging from neurodegenerative disorders like Parkinson’s disease to cardiovascular conditions, autoimmune diseases, and orthopedic injuries. We will explore the potential benefits and share examples of successful stem cell therapies.
Exosomes, on the other hand, are small vesicles secreted by cells. These tiny packages contain a diverse cargo of proteins, nucleic acids, and bioactive molecules, making them important mediators of cell-to-cell communication. Exosomes derived from stem cells, also known as stem cell-derived exosomes, have gained significant attention in regenerative medicine. They possess regenerative and immunomodulatory properties, making them potential therapeutic agents for various conditions. We will discuss the role of exosomes in cell communication, their sources, and their therapeutic potential in promoting tissue regeneration and treating diseases
Benefits and Challenges: Stem cell therapy and exosomes offer several advantages over traditional treatment approaches. Stem cells have the capacity to regenerate damaged tissues, potentially providing long-lasting relief and improving patient outcomes. Additionally, these therapies have shown reduced risk of immune rejection compared to conventional organ transplantation. However, challenges exist, including safety concerns, regulatory frameworks, and ethical considerations surrounding the use of embryonic stem cells. We will address these issues, providing a balanced view of the benefits and challenges associated with these innovative therapies.
Current Research and Clinical Trials: The field of stem cell therapy and exosomes is rapidly evolving, with ongoing research and clinical trials paving the way for future breakthroughs. We will highlight the latest advancements in these areas, including cutting-edge studies, clinical trials, and the potential implications for patients. Stay up-to-date with the latest developments and discover how these groundbreaking therapies are transforming the medical landscape.
Future Perspectives: As research in stem cell therapy and exosomes continues to expand, the future holds exciting possibilities. Emerging trends, technologies, and applications are on the horizon, promising improved treatment options, personalized medicine approaches, and enhanced patient care. We will explore the potential future developments and the transformative impact these therapies may have on healthcare and the medical industry as a whole.
Conclusion: Stem cell therapy and exosomes represent groundbreaking frontiers in regenerative medicine. Their regenerative potential, coupled with their ability to modulate the immune system and facilitate cell communication, opens new doors for treating previously incurable conditions. As the research progresses and clinical applications expand, we are poised for a future where these therapies revolutionize healthcare. Join us on this journey as we delve deeper into the fascinating world of stem cell therapy and exosomes